Correll, C. U.
Agid, Ofer
Crespo-Facorro, Benedicto
de Bartolomeis, Andrea
Fagiolini, Andrea
Seppälä, Niko
Howes, Oliver D.
Funding for this research was provided by:
Viatris
Article History
Accepted: 26 May 2022
First Online: 27 June 2022
Change Date: 17 August 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s40263-022-00946-w
Declarations
:
: This project was supported by an unconditional grant from Viatris to support medical writing provided by EDRA S.p.A.; the sponsor had no role in study design, collection of evidence, interpretation of data, writing the manuscript, or the decision to publish. Open access publication was funded by EDRA S.p.A. with an unconditional grant from Viatris.
: Dr. Correll has been a consultant and/or advisor to or has received honoraria from: AbbVie, Acadia, Alkermes, Allergan, Angelini, Aristo, Axsome, Cardio Diagnostics, Compass, Damitsa, Gedeon Richter, Hikma, Holmusk, IntraCellular Therapies, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MedAvante-ProPhase, MedInCell, Medscape, Merck, Mindpax, Mitsubishi Tanabe Pharma, Mylan, Neurocrine, Noven, Otsuka, Pfizer, Pharmabrain, Recordati, Relmada, Reviva, Rovi, Seqirus, Servier, SK Life Science, Sumitomo Dainippon, Sunovion, Supernus, Takeda, Teva, and Viatris. He provided expert testimony for Janssen and Otsuka. He served on a Data Safety Monitoring Board for Lundbeck, Relmada, Reviva, Rovi, and Teva. He has received grant support from Janssen and Takeda. He received royalties from UpToDate and holds stock options for Cardio Diagnostics, Mindpax, and LB Pharma. Dr. Agid has been a consultant and/or advisor to or has received honoraria as follows: Advisory Board/Consultant: Janssen-Ortho (Johnson & Johnson); Otsuka; Lundbeck; Allergan/Abbvie; Speaker: Janssen-Ortho (Johnson & Johnson); Lundbeck, Otsuka, Mylan Pharmaceuticals; HLS Therapeutics; Research Contracts: Janssen-Ortho (Johnson & Johnson); Otsuka; Boehringer Ingelheim; Neurocrine Bioscience; DiaMentis. Prof. Crespo-Facorro has received honoraria as a consultant and/or advisor to Angelini, Janssen/J&J, Lundbeck, Otsuka and Viatris. Dr. de Bartolomeis has participated in advisory boards, lectures and unrestricted presentations sponsored by Trivia- Mylan. Dr. Fagiolini is /has been a consultant and/or a speaker and/or has received research grants from: Angelini, Apsen, Boehringer Ingelheim, Lundbeck, Janssen, Viatris, Otsuka, Recordati, Sanofi Aventis, Sunovion, Glaxo Smith Kline. Dr. Seppala is a part-time employee of Viatris Finland as a Consultant counselling doctors on clozapine-related problems. He has participated as advisor/speaker in meetings organized by Viatris, Recordati, and Janssen-Cilag. Dr. Howes is a part-time employee of H. Lundbeck A/S and has received investigator-initiated research funding from and/or participated in advisory/ speaker meetings organized by Angellini, Autifony, Biogen, Boehringer-Ingelheim, Eli Lilly, Heptares, Global Medical Education, Invicro, Jansenn, Lundbeck, Neurocrine, Otsuka, Sunovion, Rand, Recordati, Roche and Viatris/ Mylan.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: CC and OH initiated the project. All authors were involved in literature searching and analysis for one or more of the main topics, and initial drafting of the corresponding sections. All authors critically revised the work and approved the final version of the manuscript for publication.